dabigatran has been researched along with alpha-synuclein in 1 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (alpha-synuclein) | Trials (alpha-synuclein) | Recent Studies (post-2010) (alpha-synuclein) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 10,821 | 29 | 8,011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abd El Fattah, MA; Ahmed, LA; El-Sayeh, BM; Kandil, EA; Sayed, RH | 1 |
1 other study(ies) available for dabigatran and alpha-synuclein
| Article | Year |
|---|---|
Modulatory Role of Nurr1 Activation and Thrombin Inhibition in the Neuroprotective Effects of Dabigatran Etexilate in Rotenone-Induced Parkinson's Disease in Rats.
Topics: alpha-Synuclein; Animals; Dabigatran; Dopamine; Dopaminergic Neurons; Inflammation; Male; Neostriatum; Neuroprotective Agents; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinson Disease; Rats, Wistar; Rotenone; Substantia Nigra; Thrombin | 2018 |